单克隆抗体的免疫原性和 HLA 单倍型预测易患病人群的潜在用途。
Immunogenicity of Monoclonal Antibodies and the Potential Use of HLA Haplotypes to Predict Vulnerable Patients.
机构信息
Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, Netherlands.
出版信息
Front Immunol. 2022 Jun 17;13:885672. doi: 10.3389/fimmu.2022.885672. eCollection 2022.
Abstract
The use of monoclonal antibodies (mAbs) in the clinic has successfully expanded to treatment of cancer, viral infections, inflammations, and other indications. However, some of the classes of mAbs that are used in the clinic show the formation of anti-drug antibodies (ADAs) leading to loss of efficacy. This review describes ADA formation for the various mAbs, and its clinical effect. Lastly, this review considers the use of HLA-haplotypes as biomarkers to predict vulnerability of patients sensitive to formation of ADAs.
摘要
单克隆抗体（mAbs）在临床上的应用已成功扩展到癌症、病毒感染、炎症等适应症的治疗。然而，临床上使用的一些 mAbs 类别会导致抗药物抗体（ADA）的形成，从而导致疗效丧失。本综述描述了各种 mAbs 的 ADA 形成及其临床效果。最后，本综述考虑了使用 HLA 单倍型作为生物标志物来预测对 ADA 形成敏感的患者的易感性。
相似文献
1
Immunogenicity of Monoclonal Antibodies and the Potential Use of HLA Haplotypes to Predict Vulnerable Patients.单克隆抗体的免疫原性和 HLA 单倍型预测易患病人群的潜在用途。
Front Immunol. 2022 Jun 17;13:885672. doi: 10.3389/fimmu.2022.885672. eCollection 2022.
2
Anti-drug antibodies in the current management of cancer.癌症当前治疗中的抗药抗体
Cancer Chemother Pharmacol. 2022 May;89(5):577-584. doi: 10.1007/s00280-022-04418-2. Epub 2022 Mar 25.
3
Antidrug Antibodies Against Immune Checkpoint Blockers: Impairment of Drug Efficacy or Indication of Immune Activation?针对免疫检查点抑制剂的抗体：是药效受损还是免疫激活的指征？
Clin Cancer Res. 2020 Feb 15;26(4):787-792. doi: 10.1158/1078-0432.CCR-19-2337. Epub 2019 Nov 22.
4
Correlation between HLA haplotypes and the development of antidrug antibodies in a cohort of patients with rheumatic diseases.风湿性疾病患者队列中HLA单倍型与抗药抗体产生之间的相关性。
Biologics. 2018 Jan 31;12:37-41. doi: 10.2147/BTT.S145941. eCollection 2018.
5
Immunogenicity of pembrolizumab in patients with advanced tumors.帕博利珠单抗治疗晚期肿瘤患者的免疫原性。
J Immunother Cancer. 2019 Aug 8;7(1):212. doi: 10.1186/s40425-019-0663-4.
6
Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges.肿瘤学中抗药物抗体的形成：临床相关性与挑战
Oncologist. 2016 Oct;21(10):1260-1268. doi: 10.1634/theoncologist.2016-0061. Epub 2016 Jul 20.
7
Pros and cons of the immunogenicity of monoclonal antibodies in cancer treatment: a lesson from autoimmune diseases.癌症治疗中单克隆抗体免疫原性的优缺点：自身免疫性疾病的教训。
Immunotherapy. 2019 Feb;11(3):241-254. doi: 10.2217/imt-2018-0081.
8
Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis.司库奇尤单抗，一种全人源抗白细胞介素-17A 单克隆抗体，在中重度斑块型银屑病患者中显示出最小的免疫原性。
Br J Dermatol. 2017 Mar;176(3):752-758. doi: 10.1111/bjd.14965. Epub 2016 Nov 22.
9
Evaluation of Immunogenicity of Nivolumab Monotherapy and Its Clinical Relevance in Patients With Metastatic Solid Tumors.纳武单抗单药治疗在转移性实体瘤患者中的免疫原性评估及其临床相关性
J Clin Pharmacol. 2017 Mar;57(3):394-400. doi: 10.1002/jcph.818. Epub 2016 Sep 27.
10
Novel immune check point inhibiting antibodies in cancer therapy-Opportunities and challenges.癌症治疗中的新型免疫检查点抑制抗体：机遇与挑战。
Drug Resist Updat. 2017 Jan;30:39-47. doi: 10.1016/j.drup.2017.02.001. Epub 2017 Feb 4.
引用本文的文献
1
Exploring the role of APRIL in autoimmunity: implications for therapeutic targeting in systemic lupus erythematosus, rheumatoid arthritis, and Sjögren's syndrome.探索增殖诱导配体（APRIL）在自身免疫中的作用：对系统性红斑狼疮、类风湿关节炎和干燥综合征治疗靶点的启示
Front Immunol. 2025 Aug 1;16:1523392. doi: 10.3389/fimmu.2025.1523392. eCollection 2025.
2
Molecular Insight into the Role of HLA Genotypes in Immunogenicity and Secondary Refractoriness to Anti-TNF Therapy in IBD Patients.对HLA基因型在炎症性肠病患者免疫原性及抗TNF治疗继发性难治性中作用的分子洞察
Int J Mol Sci. 2025 Jul 28;26(15):7274. doi: 10.3390/ijms26157274.
3
Targeting Aging Hallmarks with Monoclonal Antibodies: A New Era in Cancer Immunotherapy and Geriatric Medicine.用单克隆抗体靶向衰老特征：癌症免疫疗法和老年医学的新时代。
Int J Mol Sci. 2025 May 22;26(11):4982. doi: 10.3390/ijms26114982.
4
Advances in Therapeutics for Chronic Lung Diseases: From Standard Therapies to Emerging Breakthroughs.慢性肺病治疗进展：从标准疗法到新兴突破
J Clin Med. 2025 Apr 30;14(9):3118. doi: 10.3390/jcm14093118.
5
Preclinical characterization of an active immunotherapy targeting calcitonin gene-related peptide.靶向降钙素基因相关肽的主动免疫疗法的临床前特征分析
Commun Med (Lond). 2025 Apr 29;5(1):145. doi: 10.1038/s43856-025-00870-2.
6
Anti-Drug Antibody Response to Therapeutic Antibodies and Potential Mitigation Strategies.针对治疗性抗体的抗药抗体反应及潜在缓解策略
Biomedicines. 2025 Jan 26;13(2):299. doi: 10.3390/biomedicines13020299.
7
Current use and development of monoclonal antibodies for the treatment of systemic lupus erythematosus: a review.用于治疗系统性红斑狼疮的单克隆抗体的当前应用与发展：综述
Antib Ther. 2024 Dec 26;8(1):47-55. doi: 10.1093/abt/tbae033. eCollection 2025 Jan.
8
Imaging of tumor-associated macrophage dynamics during immunotherapy using a CD163-specific nanobody-based immunotracer.使用基于CD163特异性纳米抗体的免疫示踪剂对免疫治疗期间肿瘤相关巨噬细胞动力学进行成像。
Proc Natl Acad Sci U S A. 2024 Dec 24;121(52):e2409668121. doi: 10.1073/pnas.2409668121. Epub 2024 Dec 18.
9
Immunogenicity of Therapeutic Antibodies Used for Inflammatory Bowel Disease: Treatment and Clinical Considerations.用于炎症性肠病的治疗性抗体的免疫原性：治疗与临床考量
Drugs. 2025 Jan;85(1):67-85. doi: 10.1007/s40265-024-02115-3. Epub 2024 Nov 13.
10
Modular design of bi- and multi-specific knob domain fusions.双特异性和多特异性 knob 结构域融合物的模块化设计。
Front Immunol. 2024 Mar 27;15:1384467. doi: 10.3389/fimmu.2024.1384467. eCollection 2024.
本文引用的文献
1
Allelic variation in HLA-DRB1 is associated with development of antidrug antibodies in cancer patients treated with atezolizumab that are neutralizing in vitro.HLA-DRB1 等位基因变异与接受阿特珠单抗治疗的癌症患者产生体外中和性抗药物抗体有关。
Clin Transl Sci. 2022 Jun;15(6):1393-1399. doi: 10.1111/cts.13264. Epub 2022 Apr 8.
2
Development and Evaluation of Competitive Inhibitors of Trastuzumab-HER2 Binding to Bypass the Binding-Site Barrier.曲妥珠单抗-HER2结合竞争性抑制剂的开发与评估以绕过结合位点障碍
Front Pharmacol. 2022 Feb 18;13:837744. doi: 10.3389/fphar.2022.837744. eCollection 2022.
3
Serum etanercept concentrations in relation to disease activity and treatment response assessed by ultrasound, biomarkers and clinical disease activity scores: results from a prospective observational study of patients with rheumatoid arthritis.血清依那西普浓度与超声、生物标志物和临床疾病活动评分评估的疾病活动和治疗反应的关系：来自类风湿关节炎患者前瞻性观察研究的结果。
RMD Open. 2021 Dec;7(3). doi: 10.1136/rmdopen-2021-001985.
4
Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1).评估阿替利珠单抗的免疫原性：临床药理学（第一部分）。
Clin Transl Sci. 2022 Jan;15(1):130-140. doi: 10.1111/cts.13127. Epub 2021 Aug 25.
5
Panitumumab: A Review of Clinical Pharmacokinetic and Pharmacology Properties After Over a Decade of Experience in Patients with Solid Tumors.帕尼单抗：超过十年在实体瘤患者中的临床药代动力学和药理学经验回顾。
Adv Ther. 2021 Jul;38(7):3712-3723. doi: 10.1007/s12325-021-01809-4. Epub 2021 Jun 18.
6
Pharmacokinetics, Immunogenicity and Safety Study for SHR-1309 Injection and Perjeta® in Healthy Chinese Male Volunteers.SHR-1309注射液与帕捷特®在健康中国男性志愿者中的药代动力学、免疫原性及安全性研究。
Front Pharmacol. 2021 Jun 2;12:660541. doi: 10.3389/fphar.2021.660541. eCollection 2021.
7
Letter: genetic variation in the HLA-DQA1*05 allele predicts tumour necrosis factor-α antagonist immunogenicity - does location matter?信函：HLA-DQA1*05等位基因的遗传变异可预测肿瘤坏死因子-α拮抗剂的免疫原性——位置重要吗？
Aliment Pharmacol Ther. 2021 May;53(9):1055-1056. doi: 10.1111/apt.16338.
8
Trastuzumab immunogenicity development in patients' sera and in laboratory animals.曲妥珠单抗在患者血清和实验动物中的免疫原性发展。
BMC Immunol. 2021 Feb 19;22(1):15. doi: 10.1186/s12865-021-00405-z.
9
The role of IgE specific for galactose-α-1,3-galactose in predicting cetuximab induced hypersensitivity reaction: a systematic review and a diagnostic meta-analysis.IgE 特异性针对半乳糖-α-1,3-半乳糖预测西妥昔单抗诱导的过敏反应的作用：系统评价和诊断荟萃分析。
Sci Rep. 2020 Dec 7;10(1):21355. doi: 10.1038/s41598-020-78497-7.
10
Randomized Comparative Clinical Study of First Global Omalizumab Biosimilar with Innovator Product in Moderate to Severe Persistent Asthma.首个全球奥马珠单抗生物类似药与原研产品用于中重度持续性哮喘的随机对照临床研究
J Assoc Physicians India. 2020 Dec;68(12):61-65.
Zotero 插件